<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720613</url>
  </required_header>
  <id_info>
    <org_study_id>1711V9241</org_study_id>
    <nct_id>NCT03720613</nct_id>
  </id_info>
  <brief_title>Risk of Major Adverse Cardiovascular Events for Naldemedine and Other Medications for Opioid Induced Constipation in Adults With Chronic Non-Cancer Pain</brief_title>
  <official_title>Risk of Major Adverse Cardiovascular Events Among Users of Naldemedine Compared With Other Medications Used for Opioid Induced Constipation in Adult Patients With Chronic Non-Cancer Pain in a Healthcare Claims Database</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioDelivery Sciences International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HealthCore, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BioDelivery Sciences International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research objective is to characterize the risk of a major adverse cardiovascular event
      (MACE) among new users of naldemedine versus new users of lubiprostone and new users of
      naloxegol as comparator opioid induced constipation (OIC) medications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with a Major Adverse Cardiovascular Event</measure>
    <time_frame>5 years</time_frame>
    <description>A composite of major adverse cardiovascular events, cardiovascular (CV) death, nonfatal myocardial infarction (MI), and non-fatal stroke.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Cardiovascular Death</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Nonfatal Myocardial Infarction</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Nonfatal Stroke</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">34532</enrollment>
  <condition>Opioid-induced Constipation</condition>
  <arm_group>
    <arm_group_label>Naldemedine</arm_group_label>
    <description>Patients with chronic non-cancer pain who initiated naldemedine treatment for opioid-induced constipation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lubiprostone</arm_group_label>
    <description>Patients with chronic non-cancer pain who initiated lubiprostone treatment for opioid-induced constipation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naloxegol</arm_group_label>
    <description>Patients with chronic non-cancer pain who initiated naloxegol treatment for opioid-induced constipation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naldemedine</intervention_name>
    <description>0.2 mg tablet once a day at any time with or without food</description>
    <arm_group_label>Naldemedine</arm_group_label>
    <other_name>Symproic®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lubiprostone</intervention_name>
    <description>0.024 mg twice a day [adjust dose based on liver function]</description>
    <arm_group_label>Lubiprostone</arm_group_label>
    <other_name>Amitiza®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxegol</intervention_name>
    <description>25 mg tablet once a day in morning, 1 hour before or 2 hours after food</description>
    <arm_group_label>Naloxegol</arm_group_label>
    <other_name>Movantik®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include new users of naldemedine or one of the comparator OIC
        medications (lubiprostone or naloxegol) who satisfy all of the inclusion criteria and none
        of the exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one dispensing of naldemedine or lubiprostone or naloxegol without prior use
             in the database of either medication (index date)

          -  At least two dispensings of opioids within six months prior to and including the index
             date, with at least a combined 31 cumulative days supply

          -  At least 18 years of age or older on the index date

          -  At least six months of continuous health plan coverage that includes medical and
             pharmacy benefits prior to and including the index date

        Exclusion Criteria:

          -  Any acute MACE (non-fatal MI or non-fatal stroke) within six months before or on the
             index date

          -  Any cancer treatment or cancer pain diagnosis within six months before or on the index
             date

          -  Prior use of methylnaltrexone, alvimopan or naloxegol within six months before or on
             the index date
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Lanes</last_name>
    <role>Principal Investigator</role>
    <affiliation>HealthCore, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Todd Kunkel</last_name>
    <phone>913-940-1789</phone>
    <email>tkunkel@bdsi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tom Smith</last_name>
    <email>tsmith@bdsi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>naloxegol</keyword>
  <keyword>major adverse cardiovascular event (MACE)</keyword>
  <keyword>opioid induced constipation (OIC)</keyword>
  <keyword>lubiprostone</keyword>
  <keyword>naldemedine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxegol</mesh_term>
    <mesh_term>Lubiprostone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

